Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why
Hims & Hers stock had previously benefited from the demand for compounded GLP-1 injections and experienced a boost when the company entered this market.Hims & Hers Health Inc. (NYSE:HIMS) shares fell Wednesday following an FDA update listing Novo Nordisk's (NYSE:NVO) diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's what you need to know.
Hims & Hers健康公司（紐交所：HIMS）股價週三下跌，因FDA更新顯示諾和諾德（紐交所：NVO）的糖尿病藥物Ozempic和減重藥物Wegovy現已上市，表明可能供應穩定。以下是您需要了解的信息。
What Happened: A report from the FDA on Wednesday shows that all doses of Novo Nordisk's Ozempic and Wegovy, both GLP-1 receptor agonists, are now available. The change comes after a prolonged shortage of these drugs, which drove demand for compounded versions.
事件始末：FDA週三的報告顯示諾和諾德的Ozempic和Wegovy的所有劑量，均爲GLP-1受體激動劑，現已上市。這一變化發生在這些藥物長時間短缺後，導致對混合版本的需求增加。
Semaglutide, the active ingredient in both drugs, has been on the FDA's shortage list for over two years. During that time, compounding pharmacies — like those serving Hims & Hers — were legally allowed to create less expensive, compounded versions.
Semaglutide，這兩種藥物的活性成分，已經連續兩年以上位於FDA的短缺名單上。在此期間，像爲Hims & Hers提供服務的混合藥房合法允許製作價格更低廉的混合版本。
Hims & Hers stock had previously benefited from the demand for compounded GLP-1 injections and experienced a boost when the company entered this market.
Hims & Hers股價此前受益於對混合GLP-1注射劑的需求，並在公司進入這一市場時獲得提振。
The FDA's announcement suggests Novo Nordisk may soon meet demand, potentially removing Ozempic and Wegovy from the shortage list. Without a shortage, compounding pharmacies may lose the regulatory allowance to produce these alternatives. This may directly impact revenue for companies like Hims & Hers that rely on sales of compounded versions.
FDA的公告暗示諾和諾德可能很快滿足需求，有望將Ozempic和Wegovy從短缺名單中移除。沒有短缺的情況下，混合藥房可能失去生產這些替代品的監管許可，這可能會直接影響像Hims & Hers這樣依賴銷售混合版本的公司的營業收入。
HIMS Price Action: Hims & Hers Health shares were down 14.31% at $19.04 at market close Wednesday, according to Benzinga Pro.
HIMS股價走勢：Hims & Hers Health公司週三收盤時股價下跌14.31%，報19.04美元，據Benzinga Pro。
- Future-Proofing Cannabis Facilities: Grow America's Approach To Shifting Regulations
- 未來證明大麻設施的能力：Grow America對不斷變化的法規的應對
Image Via Shutterstock.
圖片來自Shutterstock。
譯文內容由第三人軟體翻譯。
